Melanotan II
Reviewed
Short answer
An unapproved tanning peptide. Two small older studies measured pigment and erectile effects, while serious harms appear in case reports and the supply chain is unverified. No approved product in any jurisdiction reviewed.
This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Read the study findingsAlso known as Melanotan 2 · MT-II · MT2 · cyclic alpha-MSH analogue
Part of Melanocortin peptides
Study and product details
What it is
Melanotan II is a synthetic peptide that acts on several melanocortin receptors. More exactly, it is a cyclic analogue of alpha-melanocyte-stimulating hormone. The reviewed records identify no approved melanotan II product. It is not the same molecule as afamelanotide in the approved Scenesse implant or bremelanotide in the approved Vyleesi product. Its receptor activity does not establish a safe or effective use. The Scenesse label warns that existing moles and freckles may darken. The Vyleesi label also reports areas of darker skin. Those product-label facts do not establish the safety of Melanotan II.
Type of peptide: Non-selective melanocortin receptor agonist. This describes what the substance is or how it works. It does not show that it is safe, effective, or approved.
What has been studied?
- Limited: Research is too small or incomplete, or does not directly answer this question.
- Unclear: There is not enough reliable detail about the product or research to judge.
No trial has tested whether using melanotan II makes anyone better off on any patient-centred endpoint.
Two small human studies from 1996 and 2000 measured pigmentation and erectile response; no human pharmacokinetic or intranasal data was located.
The safety record is case reports plus a review. They establish that serious events have occurred, not how often.
Unapproved supply with documented content and impurity variation means the vial is not a characterised medicine.
Products with the same ingredient can differ.
The ingredient name does not tell you everything about a product. Check its other ingredients, its form, how it enters the body, and the use and people covered by the research or approval.
None identified in the United States.
- No approved indication in any jurisdiction reviewed
What studies found
Two small studies in people found changes in pigment and sexual response, but they do not establish safe or effective use. The published harm record includes case reports of severe muscle breakdown, kidney injury, a prolonged painful erection that needed emergency treatment, and melanoma reported after melanotan use. These reports show that serious events were reported. They cannot show how often an event occurs or prove that Melanotan II caused each event.
The evidence does not show how often serious harms occur or what one person's risk is. The review found no phase 2 or phase 3 trial, no long-term safety study, no human study of nasal-spray absorption, and no comparison with afamelanotide. The case reports do not establish whether Melanotan II causes melanoma. Some reports also involved sunbeds or other ultraviolet exposure. No cohort or registry study was found. The frequency of serious harm is unknown; it is not known to be low.
Which products do these findings apply to?
A label on a vial or nasal spray does not show that its contents match the name. The reviewed records identify no approved melanotan II product or product label. Laboratory analysis of products sold as melanotan II found less material than the label claimed and found unidentified impurities.
Fact checks
5 statements checked. Read what the results mean.
“Melanotan II gives you a tan with less sun exposure.”
A three-person 1996 phase 1 pilot measured increased pigmentation in two of three subjects using a defined subcutaneous dose of characterised drug. That is a real pharmacological signal and nothing more: it does not establish magnitude, durability, reproducibility at consumer doses, nasal-spray dosing, or safety.
- What this answer is based on
- Studies of body changes in people
- Limits of this answer
- Pigmentation as a measured effect in a three-person 1996 pilot study using characterised drug; not consumer products, nasal sprays, or any claim about how much tan, for how long, or at what risk.
Sources for this fact check (2)
“Melanotan II protects you from sun damage or lowers skin cancer risk.”
No trial of any kind has tested sunburn, ultraviolet damage, or skin cancer as an endpoint. The published record runs the other way: melanoma and dysplastic naevus case reports, a review counting four melanomas emerging from existing moles during or shortly after melanotan use, and an approved melanocortin-1 agonist whose label calls for twice-yearly full-body skin examination because it can darken pre-existing naevi.
- What this answer is based on
- No reliable studies showing this health result in people
- Limits of this answer
- All protective or preventive framing, including the comparison with sunbeds.
Sources for this fact check (4)
“Melanotan II is basically the same thing as Scenesse or Vyleesi, just cheaper.”
Scenesse is a clinician-placed controlled-release implant of afamelanotide, a different molecule that binds predominantly to the melanocortin-1 receptor, approved for photosensitivity in erythropoietic protoporphyria. Vyleesi is bremelanotide, approved for a defined sexual-desire disorder in certain premenopausal women. Melanotan II is neither molecule and has no approval, no label, no established dose, and no verified vial content.
- What this answer is based on
- Official record or product label
- Limits of this answer
- Both versions of the confusion: melanotan marketed as equivalent to the approved Scenesse implant, and melanotan II marketed as a cheaper route to the approved bremelanotide effect.
Sources for this fact check (4)
Show 2 more fact checks
“Melanotan II is legal because it is sold as a research chemical.”
Research-use-only wording is a marketing label, not a legal status for human use. Selling and supplying melanotan injections is illegal in the UK. Australia's regulator treats melanotan II as a prescription-only medicine that is unapproved, and issued one supplier 27 infringement notices totalling AU$101,412. That same research-chemical channel is the one whose products were found to contain roughly 43 to 88 per cent of the labelled amount plus unidentified impurities.
- What this answer is based on
- Official record or product label
- Limits of this answer
- The legality of sale and supply, which is where enforcement in these jurisdictions is directed; it says nothing about what happens to an individual purchaser.
Sources for this fact check (3)
“The side effects are just nausea and flushing.”
Nausea is the dominant effect in the trial record, severe in 12.9 per cent of subjects at the higher dose in the 2000 study. But the published case literature also contains rhabdomyolysis and renal impairment requiring intensive care, renal infarction affecting roughly half a kidney, and acute ischaemic priapism that failed drug and irrigation treatment and required surgical decompression, a time-critical emergency carrying permanent erectile-dysfunction risk. These are case reports: they prove occurrence, not frequency. The honest statement is that the frequency of serious harm is unknown because no surveillance system exists, not that serious harm is rare.
- What this answer is based on
- Observations or reports from people
- Limits of this answer
- The completeness of the adverse-effect picture. Case reports establish that these events happened after use with temporal association; they cannot establish incidence or causation.
Sources for this fact check (4)
Risks and safety limits
Ischaemic priapism is a time-critical emergency: an erection persisting beyond about four hours needs immediate emergency care, because delay carries a risk of permanent erectile dysfunction. Anyone with a changing, darkening or new mole should be assessed by a clinician. This guide gives no dose, route, source or administration guidance, and none of the case-report harms below can be translated into a personal risk estimate.
Melanotan II is not named in the reviewed Prohibited List. S0 may apply to pharmacological substances without government approval for human treatment, but the reviewed records do not support a product-specific determination. Check the current rules with Global DRO and the governing body.
Reviewed .Check the rules for athletes ↗Read the official rules ↗Terms used in the studies
- peptide
- a short chain of amino acids
- analog
- a changed version made to act like another substance
- phase 2
- a mid-stage study in people that checks effects and safety before larger studies
- human pharmacology
- a study of how a substance changes the body in people
- mechanism
- how a substance may cause a body change
- biomarker
- a body or lab measurement, not automatically a health benefit
- agonist
- a substance that activates a receptor
- outcome
- what the study measured
Read the sources
Show 16 sources
Review history
Initial brief reviewed the 1996 and 2000 human studies and published case reports. One case report describes a prolonged painful erection that needed emergency treatment after Melanotan II use. The brief also used product-analysis data and two approved melanocortin labels only for contrast. Case reports show reported events, not how often they happen or what caused them.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.
Report a factual error